证券代码：002562 证券简称：兄弟科技 公告编号：2025-020 兄弟科技股份有限公司 第六届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 兄弟科技股份有限公司（以下简称"兄弟科技"或"公司"）第六届董事会第十六次会议通知 于 2025 年 4 月 14 日以电子邮件、OA 等形式送达公司全体董事，会议于 2025 年 4 月 24 日 以现场结合通讯表决的方式召开。本次会议应参加表决的董事 9 人，实际参加表决的董事 9 人，其中董事钱志明、李健平、周中平、刘清泉、姚武强、张福利以通讯方式出席会议，本次 会议由董事长钱志达先生主持，公司部分高级管理人员及监事列席会议。本次会议的召集、 召开及表决程序符合《中华人民共和国公司法》等法律法规、规范性文件以及《公司章程》 的有关规定。 本次会议经表决形成决议如下： 1、审议通过了《2024 年度总裁工作报告》 表决结果：9 票同意，0 票反对，0 票弃权。同意票数占总票数的 100%。 本议案已经公司董事会人力资源委员会审议通过。 2、审议通过了《2024 年度董事会工作报告》 ...

证券代码：002562 证券简称：兄弟科技 公告编号：2025-022 兄弟科技股份有限公司 关于 2024 年度拟不进行利润分配的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、公司2024年度拟不进行现金分红，也不进行资本公积金转增股本和其他形式的利润 分配，未分配利润结转至下年度。 2、公司2024年度利润分配预案不涉及《深圳证券交易所股票上市规则》第9.8.1条相关 规定的可能被实施其他风险警示的情形。 3、本次利润分配预案尚需提交公司2024年度股东大会审议。 兄弟科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开公司第六届董事会 第十六次会议、第六届监事会第十一次会议，会议审议通过了《2024 年度利润分配预案》，现 将相关情况公告如下： 一、2024年度利润分配预案的基本情况 根据天健会计师事务所（特殊普通合伙）出具的天健审【2025】7241 号《审计报告》确 认：2024 年度，归属于上市公司股东净利润 4,081.37 万元，母公司实现净利润 2,507.28 万元， 截至 2024 年 1 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 兄弟科技股份有限公司（以下简称"公司"）根据《上市公司证券发行注册管理办法》《深 圳证券交易所上市公司证券发行上市审核规则》《深圳证券交易所上市公司证券发行与承销业 务实施细则》等相关规定，拟提请股东大会授权董事会办理公司2025年度以简易程序向特定 对象发行融资总额不超过3亿元人民币且不超过最近一年末净资产20%的股票，授权期限为公 司2024年度股东大会审议通过之日起至2025年度股东大会召开之日止。具体情况如下： 一、具体内容 （一）发行股票的种类、面值和数量 本次以简易程序向特定对象发行的股票种类为境内上市的人民币普通股（A股），每股面 值为人民币1.00元。本次发行融资总额不超过3亿元人民币且不超过最近一年末净资产20%的 股票，发行股票的数量按照募集资金总额除以发行价格确定，且不超过发行前公司股本总数 的30%。 若公司股票在定价基准日至发行日期间发生送股、资本公积金转增股本或因其他原因导 致本次发行前公司总股本发生变动及本次发行价格发生调整的，则本次发行数量的上限将进 行相应调整。最终发行数量以中国 ...

Financial Performance - The company's operating revenue for 2024 reached ¥3,441,405,206.38, representing a 21.99% increase compared to ¥2,821,165,745.57 in 2023[21] - The net profit attributable to shareholders was ¥40,813,669.54, a significant turnaround from a loss of ¥175,468,814.06 in the previous year, marking a 123.26% improvement[21] - The net profit after deducting non-recurring gains and losses was ¥31,977,133.90, up 113.70% from a loss of ¥233,422,695.64 in 2023[21] - Cash flow from operating activities increased dramatically to ¥124,903,334.53, a 1,482.65% rise from ¥7,892,043.38 in the previous year[21] - Basic earnings per share improved to ¥0.04, compared to a loss of ¥0.17 in 2023, reflecting a 123.53% increase[21] - Total assets at the end of 2024 were ¥5,872,304,877.63, a slight decrease of 0.25% from ¥5,886,856,823.03 in 2023[21] - The company's net assets attributable to shareholders increased by 1.49% to ¥3,099,701,230.95 from ¥3,054,070,493.42 in 2023[21] - The weighted average return on net assets was 1.33%, a recovery from -5.48% in the previous year[21] Cash Flow and Investment - The cash flow from operating activities showed significant improvement, moving from -¥64.66 million in Q1 2024 to ¥115.10 million in Q4 2024, indicating better cash management[25] - The cash flow from operating activities for Q2 2024 was approximately ¥81.79 million, indicating a strong recovery from the previous quarter[25] - The net cash flow from operating activities surged by 1,482.65% to ¥124,903,334.53, driven by increased sales and reduced payments for engineering costs[82] - The total cash inflow from operating activities rose by 26.87% to ¥3,234,221,293.32, while cash outflow increased by 22.34% to ¥3,109,317,958.79[82] - The net cash flow from investment activities decreased by 153.70% to -¥217,409,979.04, primarily due to reduced fixed asset investments[83] - The net cash flow from financing activities fell by 119.70% to -¥24,222,094.06, attributed to a decrease in bank loan increases compared to the previous period[84] Market and Industry Insights - The vitamin market in China is projected to reach a market value of approximately $3.79 billion in 2024, with a year-over-year growth of 1.4%[31] - The global raw material pharmaceutical market is expected to grow from $214.72 billion in 2023 to $384.51 billion by 2033, with a compound annual growth rate (CAGR) of 6.0%[34] - The Chinese pharmaceutical industry is projected to achieve a revenue of approximately ¥2,976.27 billion in 2024, remaining stable compared to the previous year[35] - The demand for PEEK products in China is projected to grow at a compound annual growth rate of 16.82% from 2022 to 2027, driving increased consumption of phenol[59] Research and Development - The company holds 26 national invention patents for Vitamin B1, showcasing its strong R&D capabilities and innovation in production technology[41] - The company has established a three-tiered technology innovation mechanism, integrating internal and external technical resources, and has formed multiple innovation platforms, enhancing its R&D capabilities[47] - The company is focusing on new product development in the vitamin sector, including vitamins K3, B1, B3, and B5, aiming to enhance production capabilities and market competitiveness[79] - The company is also developing new technologies for phenol derivatives and leather additives, targeting industry-leading technical standards[79] - R&D investment increased by 10.08% to ¥147,208,394.69 in 2024, while the ratio of R&D investment to operating revenue decreased to 4.28% from 4.74% in 2023[81] Production and Capacity - The production capacity utilization rate for pharmaceutical products is 89.66%, while special chemicals have a utilization rate of 95.30%[42] - The company is currently constructing a project to produce 1,150 tons of iodine contrast agents, with phase one of the construction ongoing[42] - The company is set to complete a project with an annual production capacity of 20,000 tons of phenol and 31,100 tons of phenol derivatives by mid-2024, enhancing its position in the flavor and fragrance market[59] - The chromium salt segment, including sodium dichromate and chromium tanning agents, has been expanded through the acquisition of CISA, with a new project for 50,000 tons of inorganic chromium powder set to launch in mid-2024[61] Corporate Governance - The company emphasizes systematic and standardized management practices, integrating various information systems to optimize management functions and business processes[51] - The company has established a comprehensive employee performance evaluation and incentive mechanism, promoting long-term incentive plans for core talents[126] - The company maintains independent operations in business, personnel, assets, institutions, and finance, ensuring no interference from the controlling shareholder[130] - The company has independent financial management and decision-making processes, with no shared bank accounts with the controlling shareholder[135] Environmental and Safety Management - The company is committed to safety and environmental protection, continuously improving its management capabilities in these areas[115] - Brothers Technology has established a comprehensive wastewater treatment plant with a processing capacity of 350 m³/d, and a solid waste incinerator with a capacity of 1.8 t/h[180] - The pollution prevention facilities of Brothers Technology and its subsidiaries have been operating well, with stable and compliant pollutant emissions during the reporting period[180] - The company has implemented an environmental self-monitoring plan, with regular monitoring conducted by qualified third-party organizations, ensuring compliance with national and local standards[181] Shareholder Engagement - The company emphasizes transparency and timely information disclosure, enhancing the quality of information provided to investors[128] - The annual shareholder meeting in 2023 had an investor participation rate of 45.41%[137] - The first extraordinary shareholder meeting in 2024 had an investor participation rate of 45.73%[137] - The second extraordinary shareholder meeting in 2024 had an investor participation rate of 45.42%[137] Employee and Talent Management - The total number of employees at the end of the reporting period was 2,962, with 562 in the parent company and 2,400 in major subsidiaries[158] - The professional composition included 2,243 production personnel, 113 sales personnel, 337 technical personnel, 38 financial personnel, and 231 administrative personnel[158] - The company has established a robust human resources policy to protect employee rights and enhance job satisfaction through various welfare programs[187] Strategic Planning - The company aims to achieve vertical integration in the pharmaceutical sector through acquisitions, self-construction, and strategic partnerships[60] - The company is focusing on expanding its market presence in non-European and domestic markets, aligning with its strategic planning and annual operational goals[52] - The company will focus on core products and industry chain enhancement, aiming for a strategic transition from "manufacturing" to "manufacturing + service" model[107]

Financial Performance - The company's revenue for Q1 2025 was ¥918,891,681.54, representing a 12.10% increase compared to ¥819,723,681.99 in the same period last year[5] - Net profit attributable to shareholders was ¥20,908,132.12, a significant turnaround from a loss of ¥25,204,721.56, marking an increase of 182.95%[5] - Basic and diluted earnings per share were both ¥0.0197, up 183.12% from -¥0.0237 in the same period last year[5] - Operating profit for the current period was ¥30,090,791.09, a significant recovery from a loss of ¥23,107,114.93 in the previous period[20] - Net profit for the current period was ¥20,908,132.12, compared to a net loss of ¥25,204,721.56 in the prior period[20] - The total comprehensive income amounted to ¥25,956,540.02, down from ¥-28,824,560.31 in the previous period[21] Cash Flow and Liquidity - The net cash flow from operating activities improved by 42.77%, reaching -¥37,004,238.38, compared to -¥64,659,267.03 in the previous year[7] - Cash inflow from operating activities totaled ¥766,492,898.09, an increase from ¥727,220,276.43 in the previous period[24] - The ending balance of cash and cash equivalents was ¥367,867,143.66, compared to ¥320,940,005.54 in the previous period[25] - The company received ¥620,000,000.00 in cash from borrowings, significantly higher than ¥320,000,000.00 in the previous period[24] - The company reported a tax refund of ¥47,793,210.23, an increase from ¥36,572,406.29 in the previous period[24] Assets and Liabilities - Total assets increased by 2.74% to ¥6,032,933,030.02 from ¥5,872,304,877.63 at the end of the previous year[5] - Current liabilities decreased to ¥2,242,575,339.28 from ¥2,352,239,718.91, reflecting a reduction of 4.7%[18] - Long-term borrowings increased by 77.88% to ¥558,909,704.05, reflecting a rise in financing activities[7] - Long-term borrowings rose to ¥558,909,704.05, compared to ¥314,212,300.80 in the previous period, indicating a growth of 78.1%[18] Research and Development - Research and development expenses decreased by 42.18% to ¥24,945,781.79 from ¥43,141,215.69 year-on-year, indicating reduced R&D activity[7] - Research and development expenses were ¥24,945,781.79, down from ¥43,141,215.69, indicating a strategic shift in R&D investment[20] Strategic Initiatives - The company plans to raise a total of 4.37 billion RMB through a private placement of A-shares, adjusted from the previous 4.42 billion RMB[11] - The funds will be used for the construction of a 600-ton iodine contrast agent raw material project and to supplement working capital[11] - The company is focused on enhancing its market position through strategic fundraising and investment in new projects[11] - The company held board meetings in February and July 2023 to approve the private placement proposals, indicating ongoing strategic financial planning[10] - The company has extended the validity period for the private placement resolutions by 12 months, now set to expire on August 14, 2025[12] - The company is currently awaiting approval from the China Securities Regulatory Commission for the private placement, which remains uncertain[13] - The company has submitted the registration draft and related documents for the private placement to the Shenzhen Stock Exchange[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 52,715, with the top two shareholders holding a combined 44.34% of the shares[8] - The company’s major shareholders include Qian Zhida and Qian Zhiming, who are brothers and the controlling shareholders of the company[10] Other Income and Expenses - The company reported a significant increase in other income, which rose by 175.03% to ¥3,961,456.88 due to higher government subsidies received[7] - The company reported a credit impairment loss of ¥-4,309,087.94, which is an increase in losses compared to ¥-1,342,276.40 in the previous period[20]

Group 1 - The innovative drug sector continues to surge, with significant price increases in "white gold" (Vitamin D3), leading to sharp gains for companies like Brothers Technology and Erkang Pharmaceutical [4][8] - The A-share market shows a mixed performance with major indices fluctuating, while over 2,500 stocks are rising, indicating a broad market interest [3][4] - Key companies in the innovative drug sector, such as Kailaiying and Rongchang Bio, reported strong earnings growth, with Kailaiying's revenue increasing by 10.1% year-on-year [5][8] Group 2 - The price of feed-grade Vitamin D3 has surged from 450 RMB/kg to 600 RMB/kg domestically, with export prices reaching 75 USD/kg, marking a significant increase [8] - Erkang Pharmaceutical reported a revenue of 354 million RMB for Q1 2025, reflecting a year-on-year growth of 28.19%, with net profit soaring by 868.91% [8] - The market for innovative drugs is largely unaffected by recent tariff policies, as companies primarily engage in collaborative R&D with overseas firms, which allows them to avoid tariffs on licensing fees [5][8]

股票简称：兄弟科技 股票代码：002562 兄弟科技股份有限公司 （住所：浙江省海宁市周王庙镇联民村蔡家石桥 3 号） 2023 年度向特定对象发行 A 股股票 募集说明书 （注册稿） 保荐机构（主承销商） （住所：中国（上海）自由贸易试验区商城路 618 号） 二〇二五年四月 兄弟科技股份有限公司 2023 年度向特定对象发行 A 股股票募集说明书 声 明 本公司全体董事、监事、高级管理人员承诺募集说明书及其他信息披露资 料不存在任何虚假、误导性陈述或重大遗漏，并保证所披露信息的真实、准 确、完整。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保 证募集说明书中财务会计报告真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与 之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由 发行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担证券依法发行后因发行人经营与收 ...

国泰海通证券股份有限公司 关于 之 发行保荐书 保荐人（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 二〇二五年四月 兄弟科技股份有限公司 2023年度向特定对象发行A股股票 发行保荐书 国泰海通证券股份有限公司 深圳证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"或"本保 荐人"）接受兄弟科技股份有限公司（以下简称"兄弟科技"、"公司"或"发行 人"）的委托，担任兄弟科技本次向特定对象发行 A 股股票的保荐人。国泰海通 及其保荐代表人根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司证券发行注册管理 办法》（以下简称"《注册管理办法》"）、《证券发行上市保荐业务管理办法》（以 下简称"《保荐管理办法》"）等法律法规和中国证券监督管理委员会（以下简称 "中国证监会"）、深圳证券交易所（以下简称"深交所"）的有关规定，诚实守 信，勤勉尽责，严格按照依法制订的业务规则、行业执业规范和道德准则出具 本发行保荐书，并保证本发行保荐书的真实性、准确性和完整性。 本发行保荐书中如无特别说明，相关用语具有与《兄弟科 ...

国泰海通证券股份有限公司 关于 兄弟科技股份有限公司 2023年度向特定对象发行A股股票 之 上市保荐书 保荐人（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 二〇二五年四月 兄弟科技股份有限公司 上市保荐书 国泰海通证券股份有限公司 关于兄弟科技股份有限公司 2023 年度向特定对象发行 A 股股票 之上市保荐书 深圳证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"或"本保 荐人"）接受兄弟科技股份有限公司（以下简称"兄弟科技"、"公司"或"发 行人"）的委托，担任兄弟科技本次向特定对象发行 A 股股票的保荐人。国泰 海通及其保荐代表人根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司证券发行 注册管理办法》（以下简称"《注册管理办法》"）、《证券发行上市保荐业务 管理办法》（以下简称"《保荐管理办法》"）等法律法规和中国证券监督管理 委员会（以下简称"中国证监会"）、深圳证券交易所（以下简称"深交所"） 的有关规定，诚实守信，勤勉尽责，严格按照依法制订的业务规则、行业执业规 范和道德准则出具本上市 ...

Financial Performance - Total revenue for 2024 reached CNY 3,441,405,206.38, representing a year-on-year increase of 21.99%[4] - Operating profit was CNY 52,128,495.19, a significant turnaround from a loss of CNY 154,384,396.97 in the previous year, marking a growth of 133.77%[4] - Net profit attributable to shareholders was CNY 39,816,742.45, compared to a loss of CNY 175,468,814.06 last year, reflecting an increase of 122.69%[4] - The basic earnings per share improved to CNY 0.04 from a loss of CNY 0.17, representing a growth of 123.53%[4] - The weighted average return on net assets was 1.29%, recovering from -5.48% in the previous year[4] Assets and Equity - The company's total assets at the end of the reporting period were CNY 5,871,268,545.38, a slight decrease of 0.26% year-on-year[5] - Shareholders' equity increased by 1.46% to CNY 3,098,704,322.83 compared to the beginning of the period[5] Revenue Drivers - The increase in revenue and profit was attributed to rising prices of certain vitamin products and improved production capacity[5] Reporting and Forecasts - The company confirmed that there were no discrepancies between the reported results and previous earnings forecasts[6] - Detailed financial data will be disclosed in the 2024 annual report[7]